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THE CHARACTERIZATION OF T-CELL MANUFACTURING FOR ADOPTIVE 
T-CELL THERAPIES  
Amir Alpert, B.S. 
Advisory Professor: Gregory Lizee, Ph.D. 
Adoptive T-cell therapy using genetically modified T cells has emerged as a 
potential therapeutic option for several malignancies. Central to the production 
of the cellular therapy is the manufacturing using a stimulation, genetic 
engineering, and expansion methodology. Within this framework, there is a 
delicate balance between expansion of the cells to a therapeutically relevant 
dosage and the need to retain the proliferative potential of the ‘living drug’. I 
show that as T-cells are expanded for elongated periods of time, they lose 
their proliferative potential and become functionally senescent despite the 
presence of multiple proliferative cytokines. In addition, I show that expression 
of CD28 correlates with multiple manufacturing metrics, including final T-cell 
fold expansion. I propose that the loss of CD28 expression creates a T-cell 
expansion bottleneck in which certain T-cell clones are heavily favored 
compared to others during manufacturing. Compounding the multiple 
correlations, I performed a meta-analysis of available clinical trial data to show 
that younger patients appear to respond better to T-cell manufacturing 
involving CD28 costimulation, while older patients appear to respond better to 
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Structure Human Immune System and Antigen Presentation  
The human immune system functions to differentiate the ‘self’ from the 
‘non-self’ in a selective efficient manner to not induce autoimmunity (‘self’ 
attack ‘self’), yet it must mount a potent defense in the context of a foreign 
pathogen. The system is dissected into the innate and adaptive immune 
systems. The primary function of the innate system is to respond rapidly to an 
acute infection. While the adaptive system takes longer to response, it can 
form complex memory formation aimed at responding to future infections.  
The innate system is composed of several different levels, starting with the 
skins ability to serve as a physical barrier from the outside world. The 
digestive enzymes of the stomach and the saliva form another high order level 
aimed at destroying pathogens before they have a chance to establish 
themselves. Additionally, the complement system is composed of more than 
30 macromolecules which assist in eliminating foreign pathogens by 
complementing other arms of the immune system. The innate system is also 
composed of an active cellular arm such as granule containing neutrophils, 
basophils, eosinophils, mast cells, natural killer (NK) cells, and monocytes 
(Spiering 2015). 
Within the innate system, monocytes differentiate into dendritic cells (DCs) 
and macrophages, functioning as highly endocytic professional antigen 
presenting cells (APCs). These cells are bone marrow derived and particularly 
adept at endocytosis by which they monitor the blood and surrounding tissues 
for signs of pathogenic infections. Endocytosed particulates may be 
recognized as pathogen-associated molecular patterns (PAMPs) via toll-like 




The interactions between PAMPs and TLRs are extremely diverse, with 
examples including the recognition of bacterial lipopolysaccharide by TLR4, 
bacterial flagellin protein by TLR5, and CpG DNA by TLR9  (Akira 2006). 
Following their respective PAMP binding, TLRs primarily signal via a MyD88 
or TRIF dependent pathway, resulting in NF-κβ signaling and the secretion of 
IL-12, IL-6, tumor necrosis factor (TNF), and other inflammatory cytokines 
(Kawai and Akira 2010). PAMPs recognition in the cytosol is mediated via 
NOD-LRR and CARD helicase proteins as in the recognition of peptidoglycan 
peptides γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl 
dipeptide (MDP) by NOD1 and NOD2 (Chamaillard 2003) or the double-
stranded RNA (dsRNA) detector RIG-1(Yoneyama et al. 2004), both of which 
activate the NF-κβ pathway as well.  
While primarily associated with recognition of foreign pathogens, PAMP-
like signals may also be endogenous in nature. The injection of live or dead 
tumor cells has also been shown to be immunogenic, as in the injection of UV 
treated or untreated tumor cytosol (Shi 2000). As necrotic, and in certain 
contexts apoptotic, cells release cytosolic contents due to loss of plasma 
membrane integrity, it was theorized that there existed a class of endogenous 
sterile immunogenic compounds (Rock, Lai, and Kono 2011). Since this work, 
these compounds have been elucidated via cytosolic fractionation coupled 
immunogenic assays and have become known as damage-associated 
molecular patterns (DAMPs) underscoring their similarity in function to 
PAMPs. The molecular DAMPs signature is as complex as those of PAMPs, 
with examples including the recognition of nuclear HMGB1 protein by TLR4/2, 
ATP by P2X7, double-stranded DNA by AIM2, and a plethora of other 




Following APC activation by PAMPs or DAMPs, the APC primary function 
shifts from monitoring to antigen processing and presentation. As such, the 
activated APC will show increased expression of major histocompatibility 
complex class I (MHC-I) and class II (MHC-II). Every nucleated cell expresses 
MHC-I on the cell surface loaded with 8-11 long amino acid peptides derived 
from proteasomal degradation. Intracellular proteins are degraded either at the 
end of their functionality based on the respective protein half-life, or from a 
source of translationally defective ribosomal products (DRiPs). DRiPs are 
created from defective protein synthesis originating from defective mRNA 
transcription, incorrect reading frame usage, aborted protein complex 
formation, faulty amino acid insertion, or augmented ubiquitylation (Berglund 
et al. 2007; Dolan et al. 2011). The proteasomal cleaved short peptide 
sequences are transferred into the endoplasmic reticulum (ER) via the 
transporter associated with antigen presentation (TAP) protein complex. Once 
in the ER, the peptides are assembled with the heavy (HLA-A, B, or C) and 
light chain (B2-microglobin) of MHC-I and transferred to the cell surface via 
the Golgi transfer process (Vyas, Van der Veen, and Ploegh 2008).  
In contrast to MHC-I expression, major histocompatibility complex class II 
(MHC-II) expression is mostly restricted to the professional antigen presenting 
cells of the immune system, as in DCs, macrophages, and B cells. The alpha 
and beta chains of MHC-II (HLA-DR, HLA-DQ, and HLA-DP) are assembled 
with the invariant chain in the ER and transported to late endosomal 
compartments. Once in the endocytic compartment, the invariant chain is 
cleaved and replaced with an endocytosed protease cleaved peptide which 
are usually 15-24 amino acids in length (Neefjes et al. 2011). It should be 




antigen presenting cells, its expression can be regulated by IFN-γ and TGF-β 
in mesenchymal stem cells (Romieu-Mourez 2007), lung epithelium 
(Cunningham 1997), and melanoma tumor cells lines (Johnson et al. 2016) 
Cross Presentation and Activation of T-cells  
While MHC-I is classically considered to present intracellular degraded 
peptides, the process of cross-presentation enables MHC-I to be loaded with 
extracellular endocytosed peptides. This is particularly relevant in the context 
of DCs, especially the conventional DCs 1 subtype (cDC1) (Embgenbroich 
and Burgdorf 2018). There are two pathways for cross-presentation, a TAP-
dependent (cytosolic) or TAP-independent (vacuolar) pathway. In the cytosolic 
pathway, endocytosed antigens are transported from the endosomal 
compartments into the cytosol, where they are processed by the proteasome, 
and loaded onto MHC-I via the previously described TAP-ER pathway 
(Ackerman 2003). In the vacuolar pathway, antigens are directly processed by 
lysosomal proteases (e.g. cathepsin S) and loaded onto MHC-I independent 
of proteasomal degradation (Shen et al. 2004). As will be discussed in greater 
detail, a central feature of APC antigen presentation is to activate the CD8 T 
cell compartment of the adaptive immune system. In order to, presumably, 
maximize the chance of proper T-cell activation, DCs have a unique ability to 
alkalize their endosomal compartments and slow the process of antigen 
proteolytic degradation via the activity of NOX2 (Mantegazza et al. 2008), a 
lower expression of lysosomal cathepsins (Lennon-Duménil et al. 2002), and 
the ability to utilize endocytic receptors which show augmented lysosomal 
fusion kinetics (Chatterjee et al. 2012). These attributes, in theory, maximize 




Following DC activation by PAMPs, and to a lesser extent specific DAMPs, 
their chemoattractant phenotype changes from one of preferential 
inflammatory signal homing, characterized by the expression of CCR5 and 
CCR1, to that of lymphoid organ homing, characterized by the expression of 
CCR7 (Sallusto 1998). Additionally, there is a marked upregulation of 
costimulatory molecules CD80 and CD86 (Banchereau and Steinman 1998). 
As the activated mature DCs enter the lymphoid regions they are in a state 
which enables T cell activation in the classical 1, 2, 3 signaling model. They 
express MHC bound peptide antigens (signal 1), costimulatory molecules 
(signal 2), and pro-inflammatory cytokines (signal 3) enabling them to prime T 




















Figure 1: 1,2,3 Model of T-cell activation. Full T-cell activation requires 
multiple excitatory signals with signal 1 delivered by the stimulatory T-cell 
receptor (TCR): MHC interaction in which the peptide presenting MHC 
complex on the APC presents a peptide fragment (black circle) to the TCR. 
Signal 2 is composed of a costimulatory receptor interaction, such as the one 
between CD28 of the T cell and CD86 expressed by mature APCs. Finally, a 
pro-inflammatory growth cytokine signal is delivered from the APC to the T-
cell such as the cytokine signaling of IL-12. When these three signals are 










The T-cell lineage of the adaptive immune system is divided into αβ and γδ 
based on their somatically rearranged T-cell receptor (TCR). αβ cells make up 
the highest percentage of the T-cell compartment and are deemed as 
‘conventional’ T cells based on their recognition of MHC-peptide complexes 
(Curtin 1974). Within the αβ T cells, there also exists so called ‘non-
conventional’ T cells that recognize antigens in an MHC independent manner, 
such as mucosal-associated invariant T (MAIT) cells involved in bacterial 
immunity, invariant natural killer (iNK T) cells, and germline-encoded mycolyl-
reactive (GEM) T cells (Van Rhijn et al. 2013; Beckman 1994; Le Bourhis et 
al. 2010). In contrast, γδ cells represent a small fraction of the blood T cells, 
but they can account for nearly half of the gut resident T cells in line with their 
role in recognizing CD1 bound pyrophosate intermediates derived from 
bacterial lipid synthesis (Russano et al. 2007). By far, the conventional αβ T 
cells are the most well studied and understood with respect to T-cell 
activation, differentiation, receptor diversity, and antigen recognition (Attaf et 
al. 2015).  
The αβ TCR is a heterodimer composed of an alpha and beta strand linked 
by a disulfide bond which non-covalently associates with three different CD3 
complexes (εγ, εδ, ζζ) (Wang and Reinherz 2012). The α and β strands are 
composed of a constant membrane proximal region and a variable membrane 
distal region composed of three hypervariable complimentary determining 
regions (CDR1,2, and 3) generated via somatic V(D)J recombination. The 
process of V(D)J TCR recombination ensures that an extremely diverse set of 
TCRs exist to cover the equally diverse range of potential MHC bound 
peptides. Theoretically, as many as 1 x 1015 unique TCR recombinations are 




overestimation of the true number of unique TCRs in any one individual 
(Nikolich-Zugich, Slifka, and Messaoudi 2004).  
Structural investigations depict a diagonal binding model in which a 
relatively flat interaction occurs between the variable regions of the αβ strands 
and the MHC peptide binding groove (Garboczi et al. 2000). Upon binding to 
the MHC complex, structural rearrangements occur by which the cytosolic 
portions of the CD3ε subunit releases from the inner leaflet of the plasma 
membrane, exposing the immunoreceptor tyrosine-based activation motifs 
(ITAMs) of the CD3 cytoplasmic tails (Deford-Watts et al. 2009). In addition to 
the TCR-MHC interaction, a CD8 or CD4 coreceptor interacts with the 
conserved non-peptide bound regions of either MHC-I or MHC-II, respectively 
(Wang et al. 2001; Gao et al. 1997). It is this, primarily, bimodal coreceptor 
expression which dictates whether a T cell will be a CD8 T cell and interact 
with MHC-I-peptide complexes or whether it will be a CD4 T cell and interact 
with MHC-II peptide complexes.  
T-cell Differentiation  
Regardless of coreceptor expression, T cells are thought to differentiate in 
a linear model starting with their exit from the thymus as naive T cells (Tn), 
classically characterized by the expression of CD62L, CCR7, CD45RA, CD28, 
and CD27 (Rosa et al. 2001). As with the expression of CCR7 in mature DCs, 
these naive T cells are well suited to migrate to the lymphoid regions via the 
expression of CCR7 and CD62L (Weninger et al. 2001). For the naive T cell to 
become fully activated, it requires signaling via 1) the MHC-TCR interaction, 
2) costimulatory signaling (e.g. CD28), and 3) stimulatory cytokines (e.g. IL-2) 




For example, in the classical TCR-MHC ligation + CD28 costimulation, the IL-
2 receptor high-affinity receptor CD25 is expressed along with autocrine 
signaling IL-2 via NFAT, PI3K/Akt, and PKC-θ signaling pathways (Shaw et al. 
1988; Kane et al. 2001; Pfeifhofer-Obermair, Thuille, and Baier 2012).  
Upon receiving signals 1, 2, and 3, naive T cells enter a rapid proliferative 
state via the activation of the PI3K/AKT-mTOR pathway. However, in the 
absence of costimulation, naive T cells enter a state of anergy in which they 
fail to respond to TCR or IL-2 signaling (Xing and Hogquist 2012).  
Following activation, naive cells are thought to upregulate the apoptotic 
FAS receptor, CD95, and the shared IL-2 and IL-15β receptor, CD122 to form 
a compartment of highly proliferative stem cell memory T cells (Tscm) 
(Gattinoni et al. 2011). It remains to be elucidated as to what extent naive T 
cells remain in this state or whether all naive cells enter this state. It appears 
that reducing the activating signal can prevent further differentiation of Tscm 
as suggested by recent developments of T-cell activation in the presence of 
Akt inhibitors (Klebanoff et al. 2017) and WNT signaling agonists (Sabatino et 
al. 2016). Tscm cells continue to differentiate, in part, through the upregulation 
of the master splicing regulator RNA-binding protein heterogeneous nuclear 
ribonucleoprotein L-like (HNRPLL) (Wu et al. 2008) and the formation of the 
central memory T cell compartment (Tcm), characterized by the shift from 
CD45RA expression to CD45RO. Tcm differentiation is continued into the 
formation of the effector memory (Tem) compartment with the accompanied 
loss of CCR7 and CD62L expression, enabling them to exit the lymphoid 
regions and enter the peripheral tissues (Sallusto et al. 1999). The Tem 
compartment is phenotypically diverse in costimulation, with a mixture of cells 




In the absence of additional survival signals, Tem cells are destined to end up 
as short-lived proliferatively senescent effector memory RA (Teff or Temra) 
cells, characterized by the expression of inhibitory proteins such as killer-cell 
lectin like receptor G1 (KLRG1) (Voehringer, Koschella, and Pircher 2002). 
This linear model of T-cell differentiation (figure 2) is further supported by 
transcriptomic analysis of the different compartments as a majority of 
differentially expressed genes showed a continual increase or decrease going 
























Figure 2. Linear T-cell differentiation model. Upon T-cell stimulation, shown 
via APC ligation, Tnaive/scm cells undergo a rapid proliferation and expansion 
based on the cumulative strength of the signals received. The linear model 
suggests a progression from Tnaive/scm to Tcm, Tem, and finally to short 
lived Teff/emra cells. During this expansion, T-cells undergo phenotypic 
changes as described in the table below the diagram. Figure is adapted from 







The cytokine milieu (signal 3) which a T cell encounters has profound 
effects on their differentiation and acquisition of effector functions. CD4 T-cell 
effector function differentiation has been extensively studied, with the 
classifications of CD4 cells as Th1, Th2, Th17, Treg, or Tfh. Th1 cells are 
strong producers of cytokines related to anti-viral/tumor immunity such as IFN-
γ and TNF-α along with T-cell growth cytokines such as IL-2 and their 
differentiation is supported in the absence of IL-4 and the presence of IL-12 
(Hsieh et al. 1993). On the other hand, Th2 cells support humoral immunity via 
the production of IL-4, IL-5, and IL-6 and are preferentially differentiated in 
environments rich in IL-2 and IL-4 (Le Gros et al. 1990). Th17 cells are primed 
for production of IL-17, IL-22, and IL-21 via differentiation in environments rich 
in TGF-β, IL-6, and IL-21 (Zhou et al. 2007). Tregs act as immunosuppressive 
regulatory T cells via secretion of inhibitory cytokines such as TGF-β, IL-10, 
and IL-35 (Read, Malmström, and Powrie 2000; Asseman et al. 1999; Collison 
et al. 2007)  and expression of inhibitor receptors such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) (Oderup et al. 2006). Natural Treg 
(nTreg) form within the thymus, taking place in the context of strong TCR-
MHC interactions, while induced Tregs (iTregs) form in the periphery when 
CD4 T cells are stimulated in the presence of TGF-β and IL-2 (Blueston and 
Abbas 2003).  
Like CD4 cells, following CD8 T-cell activation, a rapid expansion and gain 
of effector function occurs which is context dependent based on the 
encountered cytokine milieu and strength of TCR signaling. In example, IL-12 
has been shown to increase the differentiation of naive CD8 T cells into Tem 
cells compared to IFN-α, which preferentially supported the development of 




dependent on the strength of TCR, costimulation, and the type of cytokines 
used, with IL-12 and strong TCR/costimulation yielding the most proliferation 
(Ramos et al. 2009). Understanding the effects of cytokine induced 
differentiation enables the use of IL-21 in the generation of clinically relevant 
antigen specific CD8 T cells, with increased expression of the CD28 
costimulatory receptor and increased production of IL-2 in effector responding 
T cells (Li, Bleakley, and Yee 2005). Similarly, the expansion of human T cells 
in the presence of IL-7 and IL-15 preserved the less differentiated 
CD62L+CD45RA+ population in comparison to expansion with IL-7,IL-15, and 
IL-2 (Cieri et al. 2013).  
Cancer Immunotherapy – Antibody  
The detailed understanding of the immune processes described have 
enabled immunotherapy to emerge as a leading cancer treatment (Couzin-
Frankel 2013). The most developed and commercially implemented form of 
immunotherapy comes in the form of antibody-based therapy, segregated 
based on whether they work independently or in combination with the patient’s 
immune system. In the immune independent form, the antibodies work to 
block or inhibit pathways that are essential for cancer cell survival as in the 
administration of Bevacizumab blockage of VEGF-A growth factor signaling 
and the inhibition of angiogenesis in colorectal, lung, breast, renal, brain, eye, 
and ovarian cancer (Viallard and Larrivee 2017). Alternatively, Rituxamab has 
been approved for the treatment of non-Hodgkin’s lymphoma where it serves 
as a depleting antibody by mediating tumor cell destruction via immune 
dependent antibody-dependent cellular toxicity and complement-dependent 




Antibody based therapy has also been used to boost the effector function 
of T-cells by blocking inhibitory pathways, so called checkpoint blockade 
therapies (CBT). The first CBT developed was against the cytotoxic T-
lymphocyte antigen 4 (CTLA-4) receptor which blocks T-cell costimulation by 
interfering with the CD28:CD80/86 signaling axis (Krummel 1995). Following 
its initial identification, the CTLA-4 antagonist Ipilimumab was approved for the 
treatment of metastatic melanoma (Schadendorf et al. 2015). Programmed 
cell death protein 1 (PD-1) expressed by T cells interacts with its tumor 
expressed ligand PD-L1 to lower TCR proximal signaling (Yokosuka et al. 
2012), with the αPD-1 antibody Nivolumab recently approved in multiple solid 
tumor indications (Prasad and Kaestner 2017). Additionally, agonists are 
being developed to stimulate T cells as in the targeting of tumor necrosis 
factor receptor family member 4-1BB, a known T-cell costimulatory receptor 
(Chester, Ambulkar, and Kohrt 2016).  
Antibody based therapies have yielded impressive results, with a 
considerable percentage of patients achieving long-term durable responses. 
These approaches have the benefit that they can potentially activate a 
widespread indiscriminate pool of T cells against a wide variety of tumor 
antigens. However, there are indications that a lack of CD8 T-cell infiltrate 
predicts a failure to respond to CBT (Chen et al. 2016). Theoretically, a lack of 
CD8 infiltrate could be overcome by increasing the number of activated tumor 
specific T cells in the patient. Adoptive cell transfer (ACT) therapy aims to 
achieve such a scenario via the ex vivo propagation of cancer specific T cells, 
followed by eventual patient infusion. ACT has been practiced in multiple 




antigen specific T cells , and 3) T-cell gene transfer (GT) cellular therapies 
(Tumeh et al. 2010).  
Cancer Immunotherapy – TILs 
TIL therapy relies on the ex vivo expansion of tumor reactive T cells 
extracted from patient biopsies, with a majority of trials using similar 
expansion protocols with only minor differences (Radvanyi 2015). The general 
process begins with the processing of tumor biopsies into single cell 
suspensions followed by culturing of in T-cell growth cytokines, such as IL-2. 
Once the T cells have grown to a certain threshold, they are processed via a 
rapid expansion protocol (REP) in which time they are given a TCR 
stimulation, high doses of growth cytokine, and irradiated feeder cells for 
costimulatory support. By the end of this process, therapeutic dosages in tens 
of billions of cells are achieved for infusion (Besser et al. 2010). While there is 
much work to do in elucidating the biomarkers that predict therapeutic 
response, several groups have found that response rates correlate with 
product phenotype and manufacturing characteristics, such as final telomere 
length, CD8 to CD4 ratio, fold expansion during manufacturing, and T cell 
persistence in vivo (Besser et al. 2010; Robbins et al. 2004; Zhou et al. 2005). 
With regards to the targeting of tumors by TILs, gene mutation represents 
a rich source for cancer associated antigens as a hallmark of cancer formation 
is the accumulation of unrepaired genetic mutations. Gene mutations create 
changes in the final protein sequence via single amino acid 
insertions/deletions, shifting the phase of the open-reading frame, or by the 
removal of a stop-codon leading to an extended translational sequence, 
leading to the production of potential neoantigens. It is estimated that as many 




from mutated genes (Coulie et al. 2014). The Rosenberg group at the National 
Cancer Institute, as well as many other labs, are currently pioneering the 
identification of these neoantigens from resected tumor samples in an effort to 
develop personalized cancer therapies (Yossef et al. 2018). Additionally, 
multiple groups have identified neoantigen reactive T cells in infused TIL 
products, with examples of products that contain up to 12%of T cells 
recognizing a single mutation (Lu et al. 2014; Cohen et al. 2015). Though 
there are examples of TILs against shared neoantigens, such as KRAS 
“hotspot” mutation G12D (Tran et al. 2016), the majority of TILs target 
unidentified or unique neoantigens, making it a truly personalized medicine.  
In addition to neoantigens, tumors express more categories of MHC 
expressed cancer associated antigens, such as cancer associated viral 
antigens and cancer-germline antigens. The viral antigens are of high interest 
as it is estimated that nearly one-sixth of new cancer diagnosis world-wide are 
due to infectious agents (~ two million) in which nearly two-thirds are 
associated with a viral infection (de Martel et al. 2012). Cancer-germline 
antigens, also referred to as cancer-testis antigens, are characterized by their 
expression in male germinal cells and cancerous lesions. The expression is 
nearly absent in normal healthy tissue and the expression in the male testis is 
of little concern due to the presence of a blood-testis barrier and an absence 
of HLA class I expression on germ cells (Ghafouri-Fard 2014). More than 60 
cancer-germline genes have been identified, with a majority of them being 
located on the X chromosome, with the two largest gene sets belonging to the 
melanoma antigen gene family (MAGE) (MAGEA n=12, MAGEB n=9, MAGEC 




gene families (Coulie et al. 2014). Both antigen classes have been explored 
using ex vivo T cell cloning and T-cell GT cellular therapy approaches.  
As with TIL protocols, there are several clinically applied protocols for the 
ex vivo cloning of cancer associated antigen specific T cells. In general, they 
share the common features in which a patient’s T cells are first stimulated with 
an APC to selectively activate and expand the low frequency T cells of 
interest. Nasopharyngeal carcinoma is nearly universally infected with Epsein-
Barr virus (EBV) and the viral antigens expressed are potential targets for 
ACT (Niedobitek 2000). As such, protocols have been devised by which 
autologous EBV-transformed lymphoblastoid B-cell lines serve as antigen 
presenting cells in the generation of EBV specific cytotoxic T cells through two 
rounds of ex vivo stimulation (Straathof et al. 2005). Melanoma antigen 
recognized by T cells 1 (MART-1) reactive T cells have been generated 
through the use a more laborious procedure in which MART-1 pulsed 
autologous DCs serve as APCs for IL-21 primed T cell cloning, cell-sorting, 
and REP (similar to TIL process) (Chapuis et al. 2012). While MART-1 does 
not belong to the cancer-germline class of antigens, it is exclusively expressed 
by non-vital melanocytes, making it a suitable candidate for immunotherapy. 
Additionally, other investigators have adapted this same DC based ex vivo 
cloning strategy with the use of cancer-germline antigens (Immatics US Inc, 
data not published).  
While TIL and ex vivo cloning protocols aim to expand a preexisting pool of 
cancer associated antigen specific T cells, GT cellular therapy overcomes this 
limitation by delivering a molecule with defined antigen specificity directly to a 
starting polyclonal population of T cells. For sake of simplicity, we can 




process, though they do differ in the type of gene transferred (Harris and 
Kranz 2016). The GT approaches can be divided in to chimeric antigen 
receptor (CAR) and TCR transfer based on the molecule delivered. 
Cancer Immunotherapy – Gene Therapy 
CARs are synthetic cell surface receptors, composed of an antibody 
derived single chain variable fragment (scFv) fused to a linker transmembrane 
domain, attached to an activating signaling intracellular domain (June and 
Sadelain 2018). The scFv enables the recognition of extracellular antigens 
with high affinity in an MHC independent manner, which enables CARs to 
target tumors which have down-regulated their antigen processing machinery 
(Lichtman and Dotti 2017). First generation CAR technology utilized a singular 
CD3ζ intracellular tyrosine activation motif (ITAM), which proved ineffective in 
boosting T cell activation and persistence in vivo. Later, second generation 
CAR constructs combined the CD3ζ ITAM combined with costimulatory 
domains from CD28 or 4-1BB (Sadelain, Brentjens, and Riviere 2009). These 
advanced constructs showed superior functionality and formed the basis for 
the clinical success in target CD19+ B-cell malignancies and the FDA 
approval of the novel cellular immunotherapies Kymriah and Yescarta 
(Baybutt et al. 2018). While αCD19 CARs have had the most clinical success, 
CARs targeting other hematological antigens, such as B-cell maturation 
antigen have shown early signs of clinical success (Ali et al. 2016). It remains 
to be seen whether CAR technology can translate its success to solid tumors 
(Newick et al. 2017), where TCR based immunotherapies have shown more 
success.  
While CAR technology is a synthetic biology approach, TCR GT starts by 




TCRs. Clinically validated TCRs have been isolated from previously treated 
clinically responding TIL patients in the treatment of melanoma and synovial 
sarcoma (Morgan et al. 2006; Robbins et al. 2008). This approach has the 
benefit that the TCRs have shown a safety and efficacy profile in vivo. In 
contrast, clinical TCRs have been isolated via the vaccination of human HLA 
transgenic mice followed by the cloning of the TCRs from reactive T-cell 
populations (Johnson et al. 2009). This approach has the benefit that it may 
yield high avidity TCRs that have bypassed human thymic selection, though it 
is hindered by potential immunogenicity against the transferred TCRs in vivo. 
Additionally, clinical TCRs have been created via ex vivo T-cell stimulation 
cloning approaches in which healthy donor T cells are stimulated with MHC-
peptide loaded artificial APCs (Walter et al. 2003). This strategy ensures that 
the TCR has gone through human thymic selection, increasing the safety 
profile, though these TCRs are likely of lower TCR avidity and untested in 
vivo. Following identification, TCR affinity may be artificially increased by 
directed mutagenesis, though it should be noted that this approach has 
proven quite controversial following the death of patients in two separate 
clinical trials using affinity enhanced TCRs targeting MAGE-A3 (Morgan et al. 
2013; Linette et al. 2013).  
Regardless of whether it be a CAR or a TCR, the process of making the T-
cell product can be divided into five critical steps: the leukapheresis to isolate 
the patients peripheral blood mononuclear cells (PBMCs), activation and 
genetic modification of the T cells from the PBMCs with a non-viral or virally 
encoded TCR/CAR vector, expansion of the T cells to create a clinically 
relevant dose, optional lymphodepletion of the patient before T-cell infusion, 




The activation of the T-cell compartment is primarily achieved via the use of 
agonistic αCD3 with or without costimulatory stimulation via αCD28, followed 
by the expansion in, usually, IL2 (Kohl et al. 2018), though IL7 + IL15 has 
recently gained interest as it yields a more naive T-cell final product (Xu et al. 
2014).  
Specific Aims and PhD Outline 
During the expansion, T cells begin clonal expansion and acquisition of T-
cell effector functions while losing their proliferative potential and ability to 
persist in vivo (Gattinoni, Klebanoff, and Restifo 2012). Compounding this 
problem is the fact that many industry standard assays (e.g IFN-γ release and 
chromium release) are effector centric and can be anti-correlative with in vivo 
T-cell efficacy (Gattinoni, Klebanoff, et al. 2005). As effector functions are 
gained with longer T-cell manufacturing, it is perhaps the nature of these 
assays that has prevented the shortening of T-cell manufacturing protocols.  
The work described in this dissertation is directed as addressing these critical 
problems. My specific aims are to:  
1) Develop an in vitro assay aimed at predicting long-term tumor 
control rather than short-term effector function  
2) Compare the effect of ex vivo expansion durations on the quality of 
gene therapy transfer T-cells using the newly-developed assay and perform 
mechanism of action (MOA) studies 
3) Determine the clinical relevance of the MOA studies using 







In terms of the assay, I aimed to develop it to be functional based, guided 
by pre/clinical correlatives, robust with minimal manipulation, and validated 
with clinical efficacy or clinical data analysis. Towards this goal, I developed 
the “cytokine sensitivity assay” (CSA, figure 3). This assay involves the 
thawing of a T-cell final product, which is then quickly exposed to growth 
cytokines of interest, followed by the tracking of the T cell response in an 
environment devoid of T-cell receptor (TCR) stimulation.  This assay shares 
many similarities to other assays with the notable exception that the cells used 
1) were frozen and thawed to mimic the way in which the T cells will be 
infused into patients and 2) the cytokines were added in every 7 days 
compared to the usual 2-4 day regimen (Berger et al. 2008). Importantly, the 
cytokines used were either homeostatic cytokines (IL7 or IL15), known to be 
important for T-cell persistence at a steady state (Fry and Mackall 2005; 
Gattinoni, Finkelstein, et al. 2005) or IL2 which is usually given following T-cell 
















Figure 3: The cytokine sensitivity assay. The process is initiated by thawing 
a frozen T-cell product, resting the cells in the absence of any growth 
cytokines, and labelling with a proliferation dye. The cells are then exposed to 
a titration of various cytokines and the cell behavior (e.g. proliferation, 
apoptosis, division, etc.) is tracked over a 21-day period, depending on the 













Following the development of the CSA, mechanistic studies were 
performed to measure the following attributes during T-cell ex vivo expansion:  
1) Multi-parameter phenotypic flow cytometry 
2) Relative Telomere Length  
3) Whole RNA sequencing 
4) Single molecule DNA sequencing 
From the CSA results, I observed that T cells expanded for a shorter 
period of time performed significantly better than the T cells expanded for a 
longer duration .Further, it was noted that the T cells from younger healthy 
donors performed perceptively better than T cells derived from older, healthy 
donors. Therefore, I sought to understand this mechanistically.  
During the phenotypic mechanism of action studies, it was noted that there 
was an age correlated loss of the costimulatory molecule CD28. This was a 
critical observation as CD28 stimulation is often used in the manufacturing of 
T cells. This observation has been made by many other investigators (Weng, 
Akbar, and Goronzy 2009), though to my knowledge, it has not been applied 
to the field of gene transfer therapy T-cell manufacturing. In addition, many 
manufacturing metrics (e.g. total T cell fold expansion and the final CD8 to 
CD4 ratio) are correlated with the starting percentage of CD28 expression. 
Further investigations showed that the telomere length, a critical aspect of 
cellular proliferation potential (Qian, Yang, and Cao 2014), decreased during 
T-cell expansion and that this loss correlated with donor age (expected) and 
CD28 expression (unexpected). The loss of telomere length was further 





From these mechanistic studies, I propose a mechanism of T-cell 
expansion in which intrinsic (e.g. donor age or CD28 expression) or extrinsic 
(type of manufacturing performed) factors can create ex vivo bottlenecks to T-
cell clonal survival. This model would suggest that the estimated number of 
cellular divisions that a T cell would undergo during expansion is vastly 
misrepresented by commonly used methods of estimated population 
doublings (Ghassemi et al. 2018). For example, if we have a final T-cell 
product which achieved a total T-cell fold expansion of 64-fold, then a 
predicted estimate would be that each T-cell underwent eight population 
doublings according to the following equations: 
However, if there is a significant amount of cellular death, due to the 
proposed bottlenecks, then the estimated divisions per cell would be 
underestimated by this logic. To my knowledge, no one has proposed a 
system for accurately estimating the number of cell divisions per T-cell when 
starting from a polyclonal T-cell population, such as the one found in clinical T-
cell expansion protocols. I propose that this number can be accurately 
quantified for a certain percentage of T-cells by using single molecule DNA 






Fold expansion = (Final Cell # / Starting Cell #) 
 
Estimated Divisions Per Cell = Log2(Fold Expansion) 
Clonal Fold Expansion = (Final Clone # / Starting Clone #) 
 




Using the proposed formula, the proposed bottleneck model was 
supported by showing that CD28 expression correlated with the loss of T-cell 
clones during manufacturing, with the most elderly of the donors containing 
fewer unique T-cell clones by day 10 of the expansion protocol compared to 
an early post-activation time-point. Additionally, the percentage of clones 
which changed significantly relative to the total clone number correlated with 
the starting percentage of CD28 in the T-cell population.  
The clinical relevance of these findings was ultimately supported by a 
meta-analysis of current CD19 comparable CAR clinical trials (n=47 patients). 
It was determined that patients younger than 45 would likely benefit from a 
CD3 + CD28 method of T-cell manufacturing, while patients older than 45 
would likely benefit from a CD3 only method of T-cell manufacturing. It is an 
aim of my post-doctoral work to follow up with this finding among others 
















T-Cell Manufacturing  
Healthy donor whole blood was purchased from Hemacare and PBMCs 
were isolated by Ficoll gradient. PBMCs were activated for 16-24 hours in 
TexMACS (Milltenyi 130-097-196) supplemented with 5% Human AB serum 
(Gemini 100-318) media by plating at 1e6 live PBMC/mL on tissue culture 
flasks coated overnight with 1 ug/mL anti-CD3 (eBioscience 16-0037-85) and 
1 ug/mL anti-CD28 (eBioscience 16-0289-85) antibody in PBS (Lonza 17-
516F) at 4 degrees Celsius. The next day, total cells were isolated and 
resuspended to 1e6 live-cell/mL and 5 mLs were plated into a well of a 
Grex24 well plate (Wilson Wolf 80192M). Cells were either mock transduced 
or transduced with a TCR lentiviral construct (produced by Lentigen) in the 
presence of 10 ng/mL IL7 (peprotech 200-07), 100 ng/mL IL15 (peprotech 
200-15), and 10 µg/mL protamine sulfate. The next day, cells were fed with 35 
mL of complete TexMACS supplemented with IL7 and IL15 at above 
mentioned concentrations. Cells were grown for an additional 2, 5, or 8 days 
depending on the desired manufacturing time (4, 7, or 10 total days). After 
manufacturing, cells were counted and frozen down at 5e6/mL in Cyrostore10, 
placed at -80 degrees Celsius for 16-24 hours and then stored long-term at 
LN2 vapor phase until needed.  
 
PkH67 stain  
PkH67 (Sigma PKH67GL) stain was performed per manufacturer’s 
protocol with the exception that the day 4 manufactured cells were stained at 




10 manufactured cells. PkH staining was performed before the flow cytometry 
viability dye stain.  
 
Cytokine Sensitivity Assay (CSA) 
 T-cell products were thawed and rested for approximately four hours in 
TexMACS supplemented with 5% Human AB serum and 100 U/mL 
Benzonase (Sigma E10114) at 1-2e6/mL. Following resting period, cells were 
labeled with PkH and 2e5 lymphocytes were cultured in a Grex24 well flask 
with a titration of IL7, IL15, or IL2 (R&D Systems 202-IL) for a total of 21 days. 
During this time, cells were counted by volumetric flow cytometry every three 
to four days and phenotyped with memory T-cell panel every seven days. 
Cytokines were replenished every seven days to the starting concentration.  
Flow Cytometry Stain and Acquisition 
Live cells were quantified and resuspended to 1-2e6 live-cell/mL in PBS then 
stained with Live-Dead stain according to manufacturer’s protocol. Cells were 
then washed with Flow buffer and then resuspended at desired antibody 
concentrations as indicated in the tables below and stained for 15-30 minutes in 
the dark at 4 degrees Celsius, with the exception that the CCR7 stain was done 
at 37 degrees Celsius in RPMI (Gibco 11835-030) without serum. Cells were 
then washed in Flow buffer and resuspended in fixation buffer and stored at 4 
degrees Celsius until acquired on the BD Fortessa or Miltenyi MACSQuant 








Memory T - Cell Panel for Cytokine Sensitivity Assay  
Fluorochrome Antigen Clone Dilution Provider 
Catalog 
Number 
AX488 PkH  N/A N/A Sigma 
PKH67GL-
1KT 
PerCP-Cy5.5 CD3 HIT3a  80 BioLegend 300328 
PE Vb8 JR2 80 BioLegend 348104 
PE-Cy7 CD45Ro UCHL1 80 BioLegend 304230 
APC-fire750 CD95  DX2 80 BioLegend 305638 
BV421 CCR7  G043H7 80 BioLegend 353208 
Aqua Live/dead NA  400 
Thermo 
fischer L34957 
BV605 CD8   SK1 80 BD Horizon 564116 
BV650 CD27 O323 80 BioLegend 302827 
BV785 CD62L DREG56 80 BioLegend 304830 
       
Cytokine Receptor T - Cell Panel for Cytokine Sensitivity Assay  
Fluorochrome Antigen Clone Dilution Provider 
Catalog 
Number 
AX488 Vb8 JR2 80 
BD 
BioScience 555606 
PE CD127 A019D5 80 BioLegend 351304 
APC CD122 TU27 80 BioLegend 339008 
BV421 CD25  G043H7 80 BD Horizon 562442 
BV605 CD8   SK1 80 BD Horizon 564116 
      
      
Costimulation Phenotyping Panel  
Fluorochrome Antigen Clone Dilution Provider 
Catalog 
Number 
PerCP-Cy5.5 CD3 HIT3a  80 BioLegend 300328 
PE CD127 A019D5 80 BioLegend 351304 
PE-Cy7 CD57 HNK-1 80 BioLegend 359623 
APC CD122 TU27 80 BioLegend 339008 
APC-fire750 CD8  Sk1 80 
BD 
Pharmingen 560179 
BV421 CCR7  G043H7 80 BioLegend 353208 
Aqua Live/dead   400 
Thermo 
Fisher L34957 
Bright 600 KLRG1 13F12F2 80 BioLegend 138419 
BV650 CD27 O323 80 BioLegend 302827 








Telomere length determination  
Relative telomere length was determined according to manufacturers 
instructions (Dako/Agilent K5327). Briefly, T-cells were mixed at a 1:1 ratio 
with control 1301 tumor cells (4N genome). Cells were then permeabilized and 
a Telomere PNA FITC probe was hybridized overnight. The next day, a 
counter propidium iodide stain was performed to discriminate intact cells and 
the cells were acquired by flow cytometry. The telomere length of the test cells 
was calculated as a ratio to that of the control 1301 tumor cell line.  
Telomerase Activity Assay   
Relative telomere length was determined according to manufacturers 
instructions (Sigma 11854666910). Briefly, T cell lysate was isolated and 
telomeric DNA was amplified using biotinylated primers. Following the PCR, a 
colorimetric ELISA is performed to detect these biotinylated fragments and 
absorption spectrums are fit to a standard curve.  
 
CDR3 sequencing (Adaptive Biotech) and Analysis of T-cell receptor 
variable beta chain sequencing 
Immunosequencing of the CDR3 regions of human TCRβ chains was 
performed using the immunoSEQ Assay (Adaptive Biotechnologies, Seattle, 
WA).  Extracted genomic DNA was amplified in a bias-controlled multiplex 
PCR, followed by high-throughput sequencing. Sequences were collapsed 
and filtered in order to identify and quantitate the absolute abundance of each 
unique TCRβ CDR3 region for further analysis as previously described 







Statistical Analyses of TCR-β sequencing results 
Clonality was defined as 1- Peilou’s eveness (Kirsch, Vignali, and Robins 2015) and was 
calculated on productive rearrangements by:  
where Pi is the proportional abundance of rearrangement i and N is the total 
number of rearrangements.  Clonality values range from 0 to 1 and describe 
the shape of the frequency distribution: clonality values approaching 0 indicate 
a very even distribution of frequencies, whereas values approaching 1 indicate 
an increasingly asymmetric distribution in which a few clones are present at 
high frequencies. Statistical analysis was performed in R version 3.2.  
 
RNAseq (Novogene) Data Analysis  
Downstream analysis was performed using a combination of programs 
including STAR, HTseq, Cufflink and our wrapped scripts. Alignments were 
parsed using Tophat program and differential expressions were determined 
through DESeq2/edgeR. GO and KEGG enrichment were implemented by the 
ClusterProfiler. Gene fusion and difference of alternative splicing event were 
detected by Star-fusion and rMATS software   
 
RNAseq (Novogene) Reads mapping to the reference genome  
Reference genome and gene model annotation files were downloaded 
from genome website browser (NCBI/UCSC/Ensembl) directly. Indexes of the 
reference genome was built using STAR and paired-end clean reads were 
aligned to the reference genome using STAR (v2.5). STAR used the method 
of Maximal Mappable Prefix(MMP) which can generate a precise mapping 




RNAseq (Novogene) Quantification of gene expression level. 
HTSeq v0.6.1 was used to count the read numbers mapped of each gene. 
And then FPKM of each gene was calculated based on the length of the gene 
and reads count mapped to this gene. FPKM, Reads Per Kilobase of exon 
model per Million mapped reads, considers the effect of sequencing depth and 
gene length for the reads count at the same time, and is currently the most 
commonly used method for estimating gene expression levels (Mortazavi et 
al., 2008).   
 
RNAseq (Novogene) Differential expression analysis  
(For DESeq2 with biological replicates) Differential expression analysis 
between two conditions/groups (two biological replicates per condition) was 
performed using the DESeq2 R package (2_1.6.3). DESeq2 provide statistical 
routines for determining differential expression in digital gene expression data 
using a model based on the negative binomial distribution. The resulting P-
values were adjusted using the Benjamini and Hochberg’s approach for 
controlling the False Discovery Rate(FDR). Genes with an adjusted P-value 
<0.05 found by DESeq2 were assigned as differentially expressed.    (For 
edgeR without biological replicates) Prior to differential gene expression 
analysis, for each sequenced library, the read counts were adjusted by edgeR 
program package through one scaling normalized factor. Differential 
expression analysis of two conditions was performed using the edgeR R 
package (3.16.5). The P values were adjusted using the Benjamini & 
Hochberg method. Corrected P-value of 0.05 and absolute foldchange of 1 





RNAseq (Novogene) Correlations 
To allow for log adjustment, genes with 0 FPKM are assigned a value of 
0.001. Correlation were determined using the cor.test function in R with 
options set alternative =”greater” and method = “Spearman”.   
RNAseq (Novogene) Clustering     
To identify the correlation between difference, we clustered different 
samples using expression level FPKM to see the correlation using hierarchical 
clustering distance method with the function of heatmap, SOM(Self-
organization mapping) and kmeans using silhouette coefficient to adapt the 
optimal classification with default parameter in R. 
 
RNAseq (Novogene) GO and KEGG enrichment analysis of differentially 
expressed genes  
Gene Ontology (GO) enrichment analysis of differentially expressed genes 
was implemented by the cluster Profiler R package, in which gene length bias 
was corrected. GO terms with a corrected p-value less than 0.05 were 
considered significantly enriched by differential expressed genes. KEGG is a 
database resource for understanding high-level functions and utilities of the 
biological system, such as the cell, the organism and the ecosystem, from 
molecular level information, especially large-scale molecular datasets 
generated by genome sequencing and other high-through put experimental 
technologies (http://www.genome.jp/kegg/). We used cluster Profiler R 
package to test the statistical enrichment of differential expression genes in 




Chapter 1: Cytokine Sensitivity Assay (CSA) 
To investigate the role of ex vivo T-cell expansion length on T-cell fitness, 
T-cells were manufactured for 4, 7, or 10 days (see methods section for 
details). After this manufacturing, the T-cells were analyzed via the CSA and 
the following metrics were analyzed:  
1) Cell survival as measured by fold growth of T-cells 
2) Apoptosis as measured by propidium iodide and Annexin-V stain 
3) Division as measured by the dilution of proliferation dye PkH67 
4) Cytokine receptor expression as measured by flow cytometry 
5) T-cell memory phenotype as measured by flow cytometry  
As shown in the following CSA related figures, the longer expansions led 
to a dramatic reduction in the fitness of the T-cells when assessed within the 
CSA as exemplified by:  
1) Decreased T-cell survival  
2) Increased Apoptosis  
3) Decreased division rate  
4) Decreased survival of the T-naïve_scm compartment  
Of importance, as the CSA presented was performed for 21 days, each 
sample was analyzed at 7 time points and this necessitated the definition of a 
single metric to describe the temporal behavior. For this purpose, the area 
under the curve (integration) of the temporal data was calculated and is used 
as a single defining metric to represent the behavior of the sample over the 21 







Reduced T-cell proliferation with longer duration of CD3/CD28 
expansions.  
Thawed, expanded T-cells were assessed for their ability to survive in the 
presence of IL7, IL15, or IL2 in the absence of additional antigen or CD3 
stimulation. Day 4 expanded T-cells were able to substantially outgrow the 
Day 7 or Day 10 expanded T-cells in all three cytokine conditions with an 
approximately 10-, 30-, and 15-fold peak fold growth in IL7, IL15, and IL2 
(figure 4). Conversely, day 7 and day 10 expanded T cells were unable to 
sustain substantial growth in any of the cytokine conditions. Importantly, in the 
absence of all cytokines, each T-cell population died at a similar rate 













Figure 4: Lymphocyte fold growth plots from CSA with multiple 
cytokines. T-cells expanded for 4, 7, or 10 days were assessed in the 
presence of 10 ng/mL IL7 (A), 10 ng/mL IL15 (B), or 300 U/mL IL2 (C) over a 
period of 21 days with sampling every 2-3 days. Fold growth is calculated as 
the ratio of the starting T-cell number to the T-cell number at the designated 
time point. Note that each plot has a different scale on the Y-axis to facilitate 
data visualization. Best fit lines are derived by linear quadratic equations of 








The integrated survival of each fold growth curve shown in figure 4 was 
determined by calculating the area under the curve. From an analysis of three 
biological donors, there was a trend in which the day 4 expanded T cells 
outperformed the day 7 or day 10 expanded cells (figure 5). For IL2, there was 
an approximately 5-fold drop in survival between day 4 and day 7 expanded 
cells, with an approximately 2-fold drop in survival between day 7 and day 10 
expanded cells. For IL7, there was an approximately 6-fold drop in integrated 
survival between day 4 and day 7 expanded cells, with an approximately 4-
fold drop between day 7 and day 10 expanded cells. For IL15, there was an 
approximately 8-fold drop in integrated survival between day 4 and day 7 
expanded cells, with an approximately 6-fold drop between day 7 and day 10 
expanded cells. Importantly, while there was no statistical significance due to 
the large degree of donor to donor variation, there was a consistent trend in 














Figure 5: Lymphocyte fold growth plots from CSA with multiple 
cytokines. T-cells expanded for 4, 7, or 10 days were assessed in the 
presence of 10 ng/mL IL7 (black), 10 ng/mL IL15 (blue), or 300 U/mL IL2 (red) 
over a period of 21 days with sampling every 2-3 days. Integrated survival is 
the area under the curve of the fold growth plots as shown in figure 2. Each 
point represents three technical replicates of each donor with a total of 3 








Summary of cytokine sensitivity assay T-cell division.  
From the fold growth survival data, I asked whether the earlier expanded 
T-cells were able to undergo a more rapid entry into cell division compared to 
the later expanded cells. The earlier expanded cells underwent division as 
calculated by the percentage of cells which diluted the proliferation dye at 
each time point across 10 days in the CSA (figure 6). The analysis was done 
up to 10 days as the later expanded cells did not have enough cells for 
accurate analysis past day 10. For the IL2 conditions, there was an 
approximately 30% drop in the integrated division between day 4 and day 7 
expanded cells and an approximately 50% drop between day 4 and day 10 
expanded cells which was statistically significant (p=0.0307). For IL7, the 
same trend was seen with an approximately 40% drop between day 4 and day 
7 expanded cells with an approximately 80% drop between day 4 and day 10 
expanded cells which was statistically significant (p=0.0006) by ANOVA. For 
IL15, the same trend was seen with an approximately 20% drop between day 
4 and day 7 expanded cells with an approximately 40% drop between day 4 














Figure 6: Summary of division from CSA with multiple cytokines. T-cells 
expanded for 4, 7, or 10 days were assessed via in the presence of 10 ng/mL 
IL7 (black), 10 ng/mL IL15 (blue), or 300 U/mL IL2 (red) over a period of 21 
days with sampling every 2-3 days. Integrated division is calculated based on 
the percentage of lymphocytes in which at detectable dilution of PkH67 was 
detected by day 10 in the assay. Each point represents three technical 











Summary of cytokine sensitivity assay T-cell apoptosis 
Since there was an increased fold growth of the earlier expanded cells and 
an increased division, I then asked whether there was a corresponding 
decrease in apoptosis as assessed via the staining by propidium iodide (PI) 
and Annexin-V (figure 7).  
For the IL2 conditions, there was a statistically insignificant increase 
(approximately 1.8-fold) in apoptosis between day 4 and day 7 cells, while 
there was a statistically significant (p=0.0092) increase (approximately 3-fold) 
between day 4 and day 10 cells. For the IL7 conditions, there was a 
statistically insignificant increase (approximately 2-fold) in apoptosis between 
day 4 and day 7 cells, while there was a statistically significant (P<0.0001) 
increase (approximately 7-fold) between day 4 and day 10 cells. For the IL15 
conditions, there was a statistically insignificant increase (approximately 1.6- 
fold) in apoptosis between day 4 and day 7 cells, while there was a statistically 
significant (P=0.0010) increase (approximately 5.5-fold) between day 4 and 















Figure 7: Summary of apoptosis induction in CSA with multiple 
cytokines. T-cells expanded for 4, 7, or 10 days were assessed via in the 
presence of 10 ng/mL IL7 (black), 10 ng/mL IL15 (blue), or 300 U/mL IL2 (red) 
over a period of 21 days with sampling every 2-3 days. Integrated apoptosis is 
calculated based on the percentage of lymphocytes staining positive for 
propidium iodide and annexin-V by day 10 in the assay. Each point represents 
three technical replicates of each donor with a total of 3 donors shown. 









Correlations between cytokine receptor expression and cytokine 
induced survival  
The CSA is an assay that measures the response to cytokine induced 
survival, proliferation, and apoptosis. I postulated that these changes would 
correlate with the expression of the respective cytokine receptors within each 
T-cell population at the beginning of the assay. I measured the expression of 
the defining subunit of the IL2, IL7, and IL15 cytokine receptors respectively 
as IL2α receptor (CD25), IL7α receptor (CD127), and IL15β receptor (CD122) 
(figure 8 – 10). Of note, IL15β receptor is a shared subunit between the IL2 
and IL15 receptors, though it is commonly assigned to be the reactive subunit 
of the IL15 receptor. There was a strong correlation between the IL2α receptor 
expression based on percentage of lymphocytes (R2=0.82) or as the mean 
fluorescence intensity (MFI) of CD25 expression (R2=0.89) and the response 
to IL2 induced survival of in the CSA. There was no correlation between the 
IL7α receptor expression based on percentage of lymphocytes (R2=0.04) the 
response to IL7 induced survival of in the CSA. Of interest, there was a 
moderate correlation between the MFI of IL7α receptor expression (R2=0.76) 
and IL7 induced survival. There was a weak correlation between the IL15β 
receptor expression based on percentage of lymphocytes (R2=0.42) or a 
moderate correlation as the MFI of IL15β receptor expression (R2=0.67) and 













Figure 8: IL2α receptor expression correlates with area under the curve 
(AUC) fold growth in CSA response with IL2. IL2α receptor expression was 
calculated at day 0 before initiation of the CSA with IL2 by mean fluorescence 
intensity (MFI)  of IL2α receptor (red) or by the percentage of lymphocytes 
expressing IL2α receptor (black). R2 correlations are shown for each respective 
line. Each sample point is the mean of a technical replicate (n=3) for 3 total 
biological replicates. IL2α receptor expression was monitored with a BV421 
conjugated antibody. AUC represents the integration of the fold growth of the 








Figure 9: CD127 expression correlates with percentage dividing cells in 
CSA response with IL7. IL7α receptor (CD127) expression was calculated at 
day 0 before initiation of the CSA with IL7 by mean fluorescence intensity of IL7α 
receptor expression (MFI)(red) or by the percentage of lymphocytes expressing 
IL7α receptor (black). R2 correlations are shown above each respective line. Each 
sample point is the mean of a technical replicate (n=3) for 3 total biological 
replicates. IL7α receptor expression was monitored with a PE conjugated 
antibody. AUC represents the integration of the percentage of dividing cells by 






Figure 10: CD122 expression correlates with percentage dividing cells in 
CSA response with IL15. IL15β receptor (CD122) expression was calculated at 
day 0 before initiation of the CSA with IL15 by mean fluorescence intensity of 
IL15β receptor expression (MFI)(red) or by the percentage of lymphocytes 
expressing IL15β receptor (black). R2 correlations are shown above each 
respective line. Each sample point is the mean of a technical replicate (n=3) for 3 
total biological replicates. CD122 expression was monitored with an APC 
conjugated antibody. AUC represents the integration of the fold growth of the 









CSA shows preferential survival of distinct T-cell memory populations  
Based on the previous results, I investigated whether the survival and 
proliferation in CSA was restricted to distinct memory compartments or 
whether each T-cell memory compartment was affected equally across all 
cytokine conditions. Additionally, I wanted to determine whether the cells 
continued to differentiate during the CSA or whether the starting memory 
compartment ratios were maintained. As shown in the following three 
representative figures (figures 11 – 13), IL2 CSA induced a preferential loss of 
the earlier differentiated Tnaive_scm and Tcm phenotypes while preserving 
the later differentiated Tem and Temra phenotypes. Conversely, IL15 and IL7 
CSA maintained a nearly equal ratio between the early and later differentiated 
compartments for the day 4 expanded cells across a 21 day CSA. Only the 
day 4 expanded cells readily maintained the earlier differentiated phenotypes 
in all conditions tested, while the day 7 and day 10 expanded cells readily lost 
the earlier phenotypes and showed a marked differentiation towards later 
differentiated Tem and Temra cells. In fact, for the day 4 expanded cells in the 
IL15 and IL7 CSA at day 21 in the assay, there was still greater than 50% of 
cells restricted to the Tnaive_scm and Tcm compartments, while these 











Figure 11: T-cell memory compartments in IL2 CSA. T-cell memory 
phenotype was assessed on the starting cells and then every 7 days for the 
length of the 21-day IL2 CSA as shown in figure 3. T-cell memory phenotype 
was analyzed via CCR7 and CD45Ro expression and compartments are 
annotated in each quadrant. Data is representative of three biological 






Figure 12: T-cell memory compartments in IL15 CSA. T-cell memory 
phenotype was assessed on the starting cells and then every 7 days for the 
length of the 21-day IL15 CSA as shown in figure 3. T-cell memory phenotype 
was analyzed via CCR7 and CD45Ro expression and compartments are 






Figure 13: T-cell memory compartments in IL7 CSA. T-cell memory 
phenotype was assessed on the starting cells and then every 7 days for the 
length of the 21-day IL7 CSA as shown in figure 3. T-cell memory phenotype 
was analyzed via CCR7 and CD45Ro expression and compartments are 
annotated in each quadrant. Data is representative of three biological 





Chapter 2: Mechanism of Action (MOA) Phenotyping of Cells During 
CD3/CD28 Manufacturing 
 From the CSA, the T cells appeared to be less functional in their ability to 
respond to proliferative cytokines, with context dependent correlations to 
starting cytokine receptor expression. In addition, the increased differentiation 
in day 7 and day 10 cells is in line with the reduced proliferative capacity in the 
CSA. The data suggested that a small fraction of the day 10 expanded T-cells 
retained the ability to respond to cytokines. This observation suggested that T-
cell population heterogeneity was at play in the observed behavior. To further 
investigate this diversity and the loss of proliferative potential, I focused on 
analyzing the effect of T-cell expansion on proliferative ability by measuring: 
1) Final relative telomere length (figure 14) 
2) Telomerase activity (figure 15) 
3) Costimulatory molecule expression (figures 17 and 18) 















Telomere length reduction with elongated CD3/CD28 manufacturing  
The loss of telomere length is a hallmark of dysfunctional cells as they 
become highly differentiated and eventually senescent (Nan-Ping Weng 
1995). To investigate whether this effect was taking place in our differentially 
expanded T-cells, I used a fluorescence in situ hybridization assay to assess 
the relative telomere length (RTL) of the T-cells against an internal cell line 
control (see methods for details). For all four donors analyzed, there was a 
loss in RTL throughout the expansion protocol, with the day 4 expansion cells 
always having the highest RTL (figure 14). There was an approximate 20% 
loss in RTL between day 4 and day 7 expanded cells and an additional 10% 
loss in RTL between day 7 and day 10 expanded cells when all donors were 
grouped together. There were signs of an age bias in the data as well, with the 
younger donors, on average, having longer RTL compared to the older donors 










Figure 14: Continual loss of telomere length during CD3/CD28 T-cell 
expansion. The relative telomere length was assessed by fluorescence in situ 
hybridization relative to a tumor cell line control in 4 healthy donors. Each 
sample point represents a replicate of a technical duplicate. Donor ages: 
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Reduced telomerase activity during elongated CD3/CD28 manufacturing  
Based on the reduction in telomere length and recent publications showing 
heterogeneity in telomerase induction following CD3 + CD28 stimulation 
(Huang et al. 2017), I decided to check the levels of active telomerase via an 
enzyme linked immunosorbent assay (ELISA). There was a statistically 
insignificant reduction (approximately 10%) between day 4 and day 7 
expanded cultures (figure 15). In contrast, there was a 40% reduction in 
activity between day 4 and day 10 expanded cells which was statistically 
significant (p=0.0004) and an approximately 25% reduction between day 7 
and day 10 which was also statistically significant (p=0.0165). Taken together, 
there is an expansion correlated loss in both the RTL and the final levels of 
active telomerase with the elongated expansions producing cells which are 

















Figure 15: Reduced Telomerase Activity with Elongated CD3/CD28 T-cell 
Expansion. Telomerase activity was measured via an ELISA based 
colorimetric assay from whole cell lysate of cells taken from day 4, 7, or 10 in 
T-cell expansion. Each point represents a technical triplicate sample from a 
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Telomere length reduction correlates with the starting CD28 expression 
In recent publications, the expression of telomerase was restricted to the 
CD28 expressing cells of either the CD4 or CD8 compartment following CD3 + 
CD28 stimulation (Huang et al. 2017). Given the data from figures 14 and 15, I 
reasoned that the final relative telomere length may also correspond with this 
CD28 expressing fraction of cells. There was an R2 correlation of 0.5636 
between the starting CD28 percentage of cells in the PBMCs and the final 
relative telomere length (figure 16). This analysis was carried out from multiple 

































Figure 16: Final relative telomere length correlates with starting CD28 
expression. Relative telomere length (RTL) was calculated as described 
above for both healthy donor and cancer patient derived PBMCs. RTL is 
shown for day 10 expanded T-cells. Percentage of CD28 expressing cells 
were calculated from the starting donor PBMCs. R2 correlations are shown on 











































Loss of T-cell early memory phenotypes during CD3/CD28 
manufacturing.  
There was a distinct difference in the starting memory compartments 
between the differentially expanded cells from the CSA studies with regards to 
CCR7 and CD45Ro expression. From this observation, I decided to do a 
higher resolution analysis of the starting memory compartment differences 
between the differentially expanded samples. There was a small statistically 
insignificant difference in the Tnaive_scm compartment between day 4, 7, and 
10 (mean values of 20.03%, 11.1%, 17.47 % of CD8 cells) (figure 17). There 
was a statistically significant difference (P<0.05) within the Tcm compartment 
between day 4, 7, and 10 expanded cells (mean values 58.27, 37.73, 16.8 % 
of CD8 cells).  There was a statistically significant difference (P<0.05) within 
the Tem compartment between day 4, 7, and 10 expanded cells (mean values 
of 18.9, 48.13, and 58.9 % of CD8 cells).  There was a small statistically 
insignificant difference within the Temra compartment between day 4, 7, and 
10 expanded cells (mean values of 2.70, 3.06, and 6.80 % of CD8 cells). From 
this analysis, the major memory compartment differences were found in the 
Tcm to Tem transition, with later expanded cells containing fewer Tcm and 







Figure 17: T-Cell Differentiation During CD3/CD28 Manufacturing. 
Representative PBMCs were cultured as described previously and then 
phenotyped by flow cytometry at the indicated expansion day. Memory 
phenotypes are defined based on CD45Ro and CCR7 expression, 
Tnaive_scm = CD45Ro-CCR7+, Tcm=CD45Ro+CCR7+, 
Tem=CD45Ro+CCR7-, and Temra= CD45Ro-CCR7-. Three biological donors 
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Loss of CD28 and CD27 expression during CD3/CD28 manufacturing. 
In addition to the conventional memory compartments, I also phenotyped 
the cells for expression of costimulatory markers CD28 and CD27, both of 
which are known to be associated with increased T-cell persistence in vivo 
(Huang et al. 2006; Powell et al. 2005). During CD3 + CD28 expansion, there 
was a stepwise loss of both CD28 and CD27, with the most drastic loss by 
day 10 in the manufacturing period (figure 18). While none of the comparisons 
between day 4, 7, and 10 expanded cultures yielded statistical significance 
(P<0.05), there were trends towards significance (P=0.0520) within the 
CD27+CD28+ compartment between the day 4 and day 10 expanded cultures 
(mean values of 58.47 and 21.43% of CD8 cells). Additionally, there was a 
nearly significant enrichment (P=0.1581) in the double negative CD27-CD28- 
compartment between day 4 and day 10 expanded cells (mean values 










Figure 18: Loss of costimulation during CD3/CD28 manufacturing. CD27 
and CD28 expression was assessed via flow cytometry on day 4, 7, and 10 
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Differential gene expression analysis identifies clusters the earlier 
expanded cells as a unique cluster compared to later expanded cells.  
While the previous data suggested a phenotypic difference between the 
differentially expanded T cells, the explorations were limited to the number of 
designated targets investigated (e.g. CD28 or T-cell memory compartments). 
To widen the scope of the phenotyping studies, RNAseq was performed from 
three biological donors expanded for 4, 7, or 10 days (figure 19). From this 
sequencing, cluster analysis was performed (see methods for details), which 
revealed distinct grouping of the day 4 expanded cells compared to the day 7, 
which appeared in an intermediary cluster, while the day 10 cells appeared in 
a unique cluster of their own. This data supports a linear differentiation model 
of T-cell expansion in which gradual changes at the RNA level take place 














Figure 19: Differential gene expression seen in early manufactured cells 
by RNAseq. Three biological donors were expanded for 4, 7, or 10 days and 
then whole RNA was isolated and sent to Novogene for RNA sequencing 
analysis and bioinformatics. From this analysis, we see that there is a 
distinctly different clustering pattern of the day 4 expanded cells compared to 
the day 7 and day 10 expanded cells. The DXXX_dX nomenclature denotes 
individual donor samples followed by the day in the expansion (e.g D148_d4 
is donor D148 expanded for 4 total days). The day_x represents a grouping of 
the individual similarly expanded cells (e.g. day_4 is grouping of all day 4 




Earlier expanded cells show an increased number of differentially 
expressed genes compared to the later expanded samples.   
The whole RNA sequencing was analyzed for differentially expressed 
genes (DEGs, figure 20) between the day 4, 7, and 10 expanded cells across 
three biological donors. From this analysis, the gene expression profiles 
appear to change the most early in the manufacturing process as evident by 
the 5,078 DEGs in the day 4 vs day 7 comparison and the 5,643 DEGs in the 
day 4 vs day 10 comparison. With respect to both sets, there was a roughly 
equal distribution of up and down regulated genes. In contrast, there was 
relatively few DEGs when comparing the day 7 vs day 10 manufactured cells, 






































Figure 20: RNAseq analysis during T-cell manufacturing. 
Volcano plot representation of RNAseq data during T-cell manufacturing 
comparing (A) day 4 vs day 7, (B) day 4 vs day 10, and (C) day 7 vs day 10. 
DEGs cut-off was set to 1 fold up or down with a padj-value of less than 0.05. 








KEGG analysis highlights loss of cell cycle associated genes and an 
upregulation of apoptosis associated genes throughout manufacturing 
 In order to better understand the dramatic gene expression changes 
occurring during manufacturing, KEGG pathway analysis was performed to 
identify gene pathways that were over-represented in the differing gene sets. I 
focused on pathways that were likely related to T-cell proliferation and 
persistence based on the functionality results seen in the CSA (figures 1-5). In 
comparing the later time points to day 4 in manufacturing, there is a significant 
down regulation in DNA replication and cell cycle gene pathways. 
Compounding this effect, there was a significant up regulation in apoptosis, 
p53 signalling gene pathways during the same period in manufacturing. In 
agreement with the gene expression results in figure 18, there were very few 
significantly enriched pathways between day 7 and day 10 in manufacturing 
(figure 19). A thorough description and analysis of the respective pathways is 
reserved for the discussion section. Additionally, a manual search of the 
differentially expressed genes identified multiple highly differentially expressed 






















































Figure 21: KEGG pathway analysis during T-cell manufacturing. 
 KEGG pathway analysis was performed as described in the methods section. 
The left graphs show the pathways that are upregulated between the samples. 
The right graphs show the pathways are that are downregulated between the 
samples. For each up or down regulation, the later time point is referenced 
(i.e. day_7vsday_4_down indicates pathways that were down regulated in the 









Table 1: Genes of interest differentially expressed within apoptotic, cell 
cycle, or T-cell growth pathways. 
From the list of differentially expressed genes (DEGs), a manual search was 
performed for genes which were highly differentially expressed (>2.5 fold) and 
significant (p<0.05) between the day 4 and day 10 manufactured samples. 
Ratio of gene expression is shown as the log2(fold expression) between day 























Chapter 3: Loss of CD28 with age and the bottleneck in CD3 + CD28 T-
cell expansion 
The heterogeneity in T-cell expression profiles observed suggested that 
necessary criteria for a selective pressure existed. This pressure, in theory, 
may potentially limit the replicative potential of specific T cell populations. 
From the analysis of costimulatory molecules, it was clear that there was a 
loss of CD28 expression in the starting CD8 cells and throughout the T-cell 
expansion protocol. Reasonably, this would create two types of CD8 T cells, 
those which would benefit from the CD28 costimulation given and those that 
would not benefit. Following this train of thought, an investigation into the 
significance of CD28 loss was performed. The following figures highlight an 
intrinsic CD28 importance and the correlations that exist between the starting 
CD28 phenotype and multiple manufacturing metrics.   
 
The age correlated loss of CD28 in CD8 T cells.  
For there to be a selective pressure between donors, there must be an 
intrinsic heterogeneity between donors. From the CD28 profiling, I noticed that 
the older the donor was, the lower the starting percentage of CD8 cells which 
expressed CD28, with an R2 correlation of 0.7132 (figure 22). Of note, multiple 
other investigations have shown a similar loss of CD28 expression in the 









Figure 22: The age correlated loss of CD28 expression. Eight donors (21-
64 years old) were analyzed by flow cytometry for CD28 expression. An R2 = 
0.7132 linear correlation was observed. CD28 expression data provided by 






































CD28 starting percentage correlates with final CD8 percentage during T-
cell expansions.  
Since CD28 expression in the CD8 compartment was correlated with age, I 
reasoned that other manufacturing metrics which would depend on CD28 
expression may also be biased. At the end of T-cell expansion, the ratio of 
CD8 to CD4 cells is often measured as it is primarily the CD8 compartment 
which performs tumor cytolytic function, though cytolytic CD4 cells have been 
identified (Takeuchi and Saito 2017). There was a correlation between the 
starting CD28 expression in the CD8 cells and the final percentage of cells 
which were CD8 positive with an R2 correlation of 0.6927 (figure 23). This was 
the first sign that CD28 expression may serves as the driving force for 
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Figure 23: CD28 starting percentage correlates with final CD8 
percentage. PBMCs were cultured as described in the methods section. 
Starting CD28 percentage and final CD8 percentage were calculated by flow 
cytometry. There is an R2 correlation of 0.6927 between the starting 
percentage of CD28 and the final CD8%. CD28 expression data provided by 














CD28 starting percentage correlates with fold expansion. 
Clinical T-cell expansion protocols often measure the fold expansion of the 
final product as a metric to understand the number of population doublings 
that have taken place. By day 7 in the expansion protocol, there was a clear 
correlation between fold expansion and the starting CD28 expression level 
with an R2 correlation of 0.6493 (figure 24). This was the second piece of 
evidence supporting that the starting CD28 level was indicative of T-cell 










Figure 24: CD28 starting percentage correlates with fold expansion. 
PBMCs were cultured as described in the methods section. Starting CD28 
percentage by flow cytometry. Total fold expansion was calculated from the 
day of transduction to the day 7 in the culturing period. There is an R2 
correlation of 0.6493 between the starting percentage of CD28 and the final 
fold expansion. CD28 expression data provided by CMC department at 
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Chapter 4: Single molecule DNA sequencing supports ex vivo bottleneck in 
CD3 + CD28 T-cell expansions 
The correlations of CD28 expression with multiple manufacturing metrics 
strongly suggested that the presence or absence of CD28 may dictate the 
result of the T-cell expansion. I reasoned that CD28 expression was the ex 
vivo Darwinian pressure (bottleneck), though it did not prove or disprove a 
model in which a bottleneck was selecting against CD28-expressing cells. To 
fully examine whether the bottleneck existed, I needed a method to track 
individual T-cell clones throughout the T-cell expansions and investigate 
whether there was a significant loss of T-cell clonal frequencies, analogous to 
tracking a specific animal’s fossil records throughout history. I predicted that 
for older patients with less CD28 expression, there would be a significant loss 
in the T-cell clonal diversity because of the bottleneck. Additionally, for 
younger donors with a lot of CD28 expression, there would be relatively little 
loss in the T-cell diversity due to no significant advantage or disadvantage 
within the T-cell populations. 
From a single active T-cell expansion culture, I sampled up to 10% of the 
cells at four different time points in the expansion: post activation, and day 4, 
7, and 10 of the T-cell expansions and measured:  
1) Percentage of clones which showed differential growth patterns 
(contraction vs expansion) during the T-cell expansion 
2) Clonality of the sample as measure of the percentage of clones 
which were derived from a single clonal family  
3) Median number of cell divisions per clone  
4) Clonal richness as a normalized indicator of the number of unique 




Contraction and expansion of clones correlates with starting CD28 
percentage  
From the single culture, individual T-cell clonal frequencies were tracked 
and compared to the post-activation (day 2) time-point. From this comparison, 
clones which significantly went up and down in frequency were assessed with 
the sum being the percentage that were differentially abundant. There was a 
strong correlation between the percent differentially abundant and the starting 
CD28 percentage (R2 = 0.9726) (figure 25). The lower the amount of CD28 in 
the starting sample, the higher the percentage of clones which became 
differentially abundant. This suggests that the lack of CD28 in a certain 
population creates an ecological niche for other clones to grow into and the 
lack of CD28 creates populations which are likely to die during the T-cell 












Figure 25: Contraction and expansion of clones correlates with starting 
CD28 percentage. From 3 healthy donors, single molecule DNA sequencing 
was performed, and individual T-cell clones were tracked over time as 
described above. The percent differentially abundant represents the fraction of 
all T-cell clones by day 10 in expansion that either expanded or contracted of 
the total number of evaluable T-cell clones relative to post-activation. 
Percentage of CD28 expressing cells was calculated by flow cytometry from 
the starting PBMCs. CD28 expression data provided by CMC department of 

































Lower CD28 expressing donors show a delayed T-cell expansion with 
negative median clonal divisions.  
If the CD28 bottleneck exists in the T-cell culture, there would be an 
expected delay in the T-cell population expansion based on the starting 
percentage of cells which expressed CD28. Likewise, if all the T-cell clones 
were able to expand right away, then we would expect a positive number of 
divisions per clone early in the expansion protocol. For the low and medium 
CD28 expressing cultures, there was a negative population growth between 
the post-activation (day 2) and day 4 into the expansion (figure 26), this 
suggests a contraction in the number of cells between these two time points 
and meets the definition of a Darwinian bottleneck event. Additionally, only for 
the high CD28 expressing cultures, did we see overall positive clonal 
divisions, indicating that in this culture a high percentage of the T-cell clones 
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Figure 26: Low CD28 expressing donors show delayed T-cell expansion 
with negative clonal divisions. Population growth is calculated based on 
total viable cells and represents fold growth. Clonal divisions are calculated as 
the log2(clonal fold expansion) and represent the median value obtained, 
negative values are obtained when clonal frequency contract in a culture, 
positive values are obtained when clonal frequencies expand in a culture. All 
points are relative to the post-activation baseline and calculated to day 4 in the 
T-cell expansion process. CD28 expression data provided by CMC 






















Reduction of unique T-cell clones during expansion in donors with lower 
expression of CD28 by DNA clonal sequencing. 
If we track the number of unique T-cell clones throughout a culture to, then 
we would expect that if the bottleneck was present, there would be large 
swings in the number of unique T-cell clones post-bottleneck event. Clonal 
Richness is the measurement which calculates the number of unique T-cell 
clones normalized to the number of DNA molecule reads from sequencing. 
From the Clonal Richness calculations, there was a striking drop in the 
number of unique T-cell clones following day 4 in the expansion protocol for 
the two lower CD28 expressing starting populations (figure 27). On the other 
hand, for the highest CD28 expressing population, there was a strong 
maintenance in the number of unique T-cell clones relative to the post-
activation time-point. For cultures starting with lower CD28 expression, there 
is a drop in the number of unique T-cell clones following the peak levels post-
stimulation. This drop is presumably due to differential survival of T-cell clones 





































































































D 2 7 0 1 3 6  ( 9 3 . 4 % )
D 2 7 0 2 0 2  ( 5 4 . 3 % )
D 4 4 6 4 5  ( 3 1 . 1 % )
 
 
Figure 27: Reduction in unique T-cell clones in donors with lower CD28 
expression. Following the burst in unique clones following stimulation, there 
is a continual reduction in unique clones in donors with lower CD28 (shown in 
parenthesis in the key). The proposed bottlenecks are marked by black arrows 
and occur as the expansion protocol is elongated past day 4. Unique T-cell 
clones are derived from the number of unique DNA molecule reads of the T-
Cell receptor CDR3 region as described in the methods section. All values are 
normalized to the number of unique T-cell clones at post-activation. Dotted 
black line at value of 1 marks the point where there are fewer T-cell clones 










Results: Increased CD28 expression in starting PBMCs confers 
advantageous growth dynamics during T-cell manufacturing  
In effort to characterize the expansion of clonal populations during the T-
cell expansion, I tracked the expansion kinetics of individual T-cell clones 
during the manufacturing process. When tracking individual clones, I 
measured the clonal divisions as well as the absolute numbers of T cells 
within a T-cell clonal population. An increase in CD28 expression in starting 
PBMCs conferred an early growth advantage, with nearly two-thirds of T-cell 
clones expanding between the activation step (day 2) and day 4 in 
manufacturing (figure 28A). In contrast lower CD28 expressing starting 
populations displayed a kinetics in which most T-cell clones contracted during 
this early stage of manufacturing, with the lower CD28 population containing 
on 1.19% of early expanding clones (figure 28A). As we tracked the divisions 
of the clonal populations, it was observed that the lower CD28 sample 
displayed a non-normally distributed division pattern, while the mid and high 
CD28 population showed a more normally distributed characterization. 
Additionally, the lower the starting CD28 expression, the more divisions it took 
to reach the same number of T-cells (figure 28B). Together this data indicates 
that high CD28 starting populations undergo a more advantageous T-cell 
expansion marked by reduced T-cell contraction and a lower number of 












































Figure 28: Characterization of T-cell expansion kinetics.  
T-cell clones were tracked by clonal DNA sequencing and absolute numbers 
within each clonal population (A) was calculated during the early (day 4), mid 
(day 7), and late (day 10) of the expansion process. Median (Med), Average 
(Avg), and Total cell numbers (Tot) are inserts within each graph. (B) The 
number of divisions required to reach 1e8 total T cells was calculated. CD28 















































Younger patients have an improved response to CD19 CAR therapy when 
manufactured with CD28 co-stimulation  
To further explore any significance of the proposed ex vivo T-cell 
expansion bottleneck, I performed a clinical trial meta-analysis to investigate 
whether the loss of CD28 expression in elderly patients would create clinical 
trends. From the previous data, I reasoned that older patients would perform 
differently compared to younger patients based on the manufacturing (CD3 
alone or in conjunction with CD28).  
As T-cell therapy clinical trials are still in their infancy (40 published clinical 
trials available for analysis) and many of them are early stage trials with 
unconfirmed moieties (e.g. an untested new TCR or CAR molecule), the meta-
analysis required filtering steps to create a uniform comparable data set 
(figure 29). After filtering and compilation, I was left with 7 clinical trials 
targeting CD19 malignancies for a total for 107 patient data points.  From this 
analysis, I determined that patients younger than 45 had a better clinical 
prognosis when their cells were manufactured with the CD3 + CD28 method. 
Contrastingly, when patients were older than 45, there was a benefit to being 













Figure 29: Clinical Gene Therapy Transfer Trial Meta-Analysis. 40 clinical 
trials were analyzed and filtered based on defined selection criteria: relevance 
filter and CD19 filter, resulting in a total of 4 comparable CAR clinical trials. 
The relevance filter excluded trials that were in combination or following stem 
cell transplants, virus specific T-cell products, extensive patient toxicities, CD4 
specific trials, and complex T-cell manufacturing unseen in other trials. The 
CD19 filter was applied to compare only trials in which the target (CD19) had 
been clinically validated and with comparable manufacturing strategies (e.g. 









































































































































































































































































Clinical response rates correlate with the fold growth ex vivo in clinical trial 
against multiple myeloma  
Multiple clinical and preclinical investigations have suggested that 
phenotypically younger less differentiated T cells outperform in comparison to 
older more differentiated T cell products (see discussion for references). Based 
on the manufacturing data we have compiled (figures 23 - 28), high CD28 
expressing (younger) starting PBMCs are able to achieve a higher fold expansion 
ex vivo and yield a phenotypically less differentiated final product. Based on these 
observations, it is likely that if you manufacture T cells for same period, then 
cultures which achieve a higher fold expansion were likely derived from more 
youthful less differentiated starting PBMCs, yielding a less differentiated product, 
and potentially a more potent clinical product.  
As shown in table 3 from a αBCMA multiple myeloma CAR clinical trial, 
there was a 57% response rate when cell cultures achieved greater than 10-fold 
expansion ex vivo. In comparison, there was a 0% response rate when cultures 
failed to achieve 10-fold expansion. These observations further support the 
translational relevance of my findings and support a manufacturing centric model 













Table 3: Ex vivo manufacturing metrics correlate with clinical response 
in multiple myeloma. Data from clinical manufacturing (Ali et al. 2016) were 
combined with the clinical response rates and sorted by the fold expansion of 
CD3+ cells achieved during manufacturing. Response rates were calculated 
as the number of patients who achieved a PR or CR in relation to the total 
number of patients in the group. PR = partial response, SD = stable disease, 
CR = complete response.  
 


















MM BCMA NA 0.001/kg SD 24.89 
MM BCMA NA 0.009/kg CR 15.00 
MM BCMA NA 0.009/kg SD 13.92 
MM BCMA NA 0.003/kg PR 13.63 
MM BCMA NA 0.0003/kg SD 11.99 
MM BCMA NA 0.009/kg PR 10.96 










MM BCMA NA 0.003/kg SD 9.35 
MM BCMA NA 0.001/kg SD 5.62 
MM BCMA NA 0.003/kg SD 3.85 





As gene-transfer cellular therapies emerge for solid and liquid 
malignancies, the ex vivo manufacturing process will be continually evolving 
as we gain insight into therapeutic correlatives. It should be noted that with 
multiple forms of cellular therapy emerging, it will be an active area of 
research to understand which factors can be universally applied and which are 
unique to a specific therapy. Nonetheless, as we still do not have such a 
thorough understanding, it is practical to test and design manufacturing from 
the information derived from multiple forms of cellular therapy (e.g. TIL, ex 
vivo endogenous stimulated, and gene therapy). While there is an extensive 
literature with respect to pre-clinical correlates, given the complexity of these 
modalities, clinical data should be prioritized above any pre-clinical guidance. 
Additionally, the assays used to characterize cellular therapies should be 
heavily designed with the knowledge of the clinical correlatives.  
The work in this dissertation heavily focused on designing an in vitro assay 
to test the hypothesis that early manufactured TCR gene-transferred T cells 
would be superior to later expanded cultures in the clinically correlated criteria. 
The assay was designed to focus on the ability of T-cells to persist post-
manufacturing, which has been correlated with TIL clinical response rates 
(Robbins et al. 2004) and the ability of T-cells to expand, clinically correlated 
in recent TCR GT trials (D'Angelo et al. 2018). The hypothesis was guided by 
work from the melanoma TIL field in which responding patients were shown to 
be significantly enriched when cultured for a shortened period (Besser et al. 
2010) and pre-clinical mouse studies which emphasized the need to reduce 
the gain of effector function which accumulates as expansion proceeds 




The resulting cytokine sensitivity assay (CSA) was designed to measure 
the ability of the post-manufactured human T cells to respond to a set of 
common gamma chain cytokines (IL2, IL7, and IL15). Importantly, these 
signals were selected as they are likely to be encountered post-infusion in the 
clinic. IL2 is very often administered as an adjuvant in GT T-cell therapy 
(Robbins et al. 2011) and IL7 and IL15 are known homeostatic cytokines 
present in lymphocyte rich compartments of the body and known to drive T-
cell expansion in the periphery (De Bock et al. 2013).  
The CSA results suggested that a shorter manufacturing time, in the 
context of CD3 + CD28 manufacturing, retains the potential of the T-cells to 
respond to the growth cytokines (figure 2). This effect correlated weakly with 
the level of cytokine receptor expression (figure 6-8), suggesting that the loss 
of distinct cytokine receptors may be a factor in the observed proliferative 
senescence. In addition to the reduced proliferation, there was an increased 
rate of active apoptosis and a lack of entry into early cell division (figure 4-5). 
The increased response to growth cytokines suggests that fewer T cells would 
be needed for infusion as there would be a more dramatic expansion in vivo. 
In line with this observation, other groups have reported similar findings in the 
context of CAR T cells in which a six fold lower infusion of early minimally 
expanded T cells was superior to a longer expansion protocol (Ghassemi et 
al. 2018).  
 In addition to the loss of functionality, there was a dramatic shift in the T-
cell memory phenotype with day 4 cells retaining a Tnaive_scm and Tcm 
phenotype compared to the day 7 and day 10 expanded cells. Surprisingly, 
across the 21-day assay, in the context of IL15 and IL7 (key homeostatic 




compartments (figure 9-11). This behavior was not evident when culturing with 
IL2, perhaps due to the faster downregulation of the IL2 CD25 receptor 
compared to the IL7 CD127 and the IL15 CD122 receptors.  
 The lack of T-cell persistence in the CSA suggested that as the T-cell 
expansion was elongated, they began acquiring a senescent phenotype in 
response to homeostatic cytokines. Clinically infused TIL products have been 
shown to persist in vivo in correlation to their final telomere length (Zhou et al. 
2005) and thus I began investigating these changes as a potential correlate 
for the observed in vitro senescence.  
There was a reduction in telomere length for all donors as the expansions 
were elongated (figure 12). Additionally, a statistically significant (p<0.05) 
difference was observed for telomerase activity between the day 4, 7, and 10 
expanded T-cell products (figure 13), with the earlier expansions producing 
the highest rate of telomerase activity. Of interest was the observation that the 
final relative telomere length correlated with the starting percentage of CD28 
expressing CD8 cells (figure 14). Additionally, there was a sharpened 
reduction in the final telomere length when cancer patient derived T-cells were 
manufactured compared to healthy donors, though this is less surprising given 
the more elderly age of the cancer derived cells. This fits with recent data 
showing that only a subset of the CD28 expressing CD8 T-cells can 
upregulate telomerase following CD3 + CD28 based stimulation (Huang et al. 
2017) and recent genetic screens that have highlighted the reduced 
proliferation of T cells when CD28 is genetically deleted (Shifrut et al. 2018).   
Its noteworthy to mention that there have been recent attempts to overexpress 
telomerase to counteract the loss of telomere length and proliferative 




approaches have entered the clinic, likely due to the ability of telomerase to 
transform cells.  
 In order to more completely investigate the changes occurring during the 
expansion, I turned to whole RNA sequencing analysis. Gene cluster analysis 
clearly outlined that the day 4 expanded cells displayed a differential gene 
expression pattern compared to the day 7 and day 10 expanded T cells (figure 
17). Confirming this observation, differential gene expression analysis 
measured over 5,000 DEGs between day 4 to day 7 or day 10. Very 
surprisingly, there were fewer than 100 DEGs between day 7 and day 10 
expanded T cells (figure 18). This bimodal breakdown strongly suggests that 
during in vitro T-cell expansion, a priming occurs early in the process, likely 
dependent on the initial T-cell stimulation and cytokine milieu, like events that 
take place in vivo.   
Pathway analysis revealed a statistically significant upregulation of 
apoptosis related genes when comparing the day 4 to day 7 or day 10 
samples. This was particularly interesting given the increased apoptotic 
behavior observed in the CSA. Within the apoptotic pathway, there was a 
significant increase in apoptotic effector molecules such as CASP8, BAX, 
RIPK1, and TRADD both of which are known be critical in the intrinsic 
apoptosis pathway involving mitochondrial disruption (Gu et al. 2005). 
Intriguingly, there was also an enrichment of apoptosis inhibiting proteins such 
CFLAR (cFLIP) and XIAP, which work independently to inhibit the CASP8 
effector function and the formation of the apoptosome (He and He 2015). 
Given the heterogenous starting PBMC population, it is possible that within 
the expanding T-cell cultures, there exists subgroups of T-cell populations that 




results from CSA show that even within the later expanding cultures, there 
exists a population of T cells which remain proliferatively active (figure 2). In 
line with this finding, certain clonal populations expanded early in the 
manufacturing process while other clones contracted as measured by clonal 
DNA sequencing (figure 24A).  
As expected from stimulated T-cell cultures, there was a significant 
enrichment in T-cell stimulatory pathways, such as phosphatidylinositol 
signaling and MAPK signaling as the manufacturing length increases (figure 
19). This is not of much surprise given the known association between these 
pathways and T-cell expansion (Herrero-Sanchez et al. 2016). Of interest, is 
the contrasting reduction in cell cycle associated genes as the expansion 
length continues, with reduction in key cyclin dependent kinases CDK4/CDK6 
along with proliferating cell nuclear antigen (PCNA) (table 1). This contrasting 
gene expression would suggest that there is an immediate upregulation of 
genes responsible for cellular division, followed by a later subsequent 
upregulation of growth pathway factors. Other groups have shown an 
improvement in T-cell clinically related functionality by the inhibition of the 
PI3K pathway with small molecular inhibitors, resulting in a more naive T cell 
product with increased T cell proliferative potential (Klebanoff et al. 2017). The 
results of the CSA are very much aligned with this finding given the increased 
T-cell proliferation observed in earlier cultures which have not yet upregulated 
the PI3K pathway signaling.   
 Cytokine signaling is necessary as the third signal for T-cell proliferation 
via cytokine receptor specific JAK/STAT signaling axis (Seif et al. 2017). 
Signaling through T-cell cytokine receptors can be inhibited by the activity of 




target cytokine receptors for proteasomal degradation (Yoshimura, Naka, and 
Kubo 2007). SOCS1 is known regulator for IL-2, IL-7, and IL-15 signaling and 
was recently identified a suppressor of T-cell proliferation via a genetic 
screening study (Shifrut et al. 2018). During the expansion, there was a 
significant upregulation of SOCS2. While SOCS2 is primarily thought to 
regulate signaling through the insulin growth factor receptor, it was recently 
reported that SOCS2 deficient NK cells are hypersensitive to IL-15 (Kim et al. 
2017), suggesting that SOCS2 may have additional roles in regulating 
common gamma chain cytokine signaling during the CSA.  
The growth arrest seen in the cultures expanded for longer periods 
suggests an upregulation of proliferation inhibition pathways. A critical step in 
cellular proliferation is the downregulation of cyclin dependent kinase 
inhibitors. The major p16/pRb pathway has been shown to correlate with the 
proliferative senescence in in vitro activated human lymphocytes following 
stimulation with T-cell mitogens (Migliaccio et al. 2005). In line with this 
observation, we note that from our RNAseq data there is a nearly 2.2 fold 
increase in the expression of the p16 encoding CDKN2A mRNA as cells are 
manufactured from 4 to 10 days. While it is only a moderate change, we also 
observed a nearly 50% increase in pRB mRNA expression in the early day 4 
manufactured cells compared to day 10 manufactured.  
From the phenotyping results, there was a decline in doubly expressing 
CD27+ CD28+ T-cells throughout the expansion process. This decline is 
rather problematic given recent observations that the expression of CD27 is a 
predictor of clinical response (Fraietta et al. 2018). In the RNAseq data set, 
there was a significant loss CD86 expression during the manufacturing, 




between CD28/CD86 early in the manufacturing process. While CD86 is 
thought to be primarily expressed by APCs, there is evidence that it is 
upregulated on T cells following activation (Paine et al. 2012). Mechanistically, 
this depletion of costimulatory cells makes further expansions with CD3 + 
CD28 a compounding issue, though there is evidence that overexpression of 
CD28 may revert the phenotypic loss and act as a surrogate for additional 
expansions (Mondal et al. 2013). While an overexpression strategy may be 
more permanent, there is evidence that altering the stimulation procedure may 
preserve the expression of CD28. Researchers have shown that stimulation 
through the 4-1BB costimulatory pathway may preserve the expression of 
CD28 expressing T cells in vitro (Habib-Agahi, Jaberipour, and Searle 2009). 
It is interesting to speculate that an additional 4-1BB stimulation during the T-
cell stimulation with CD3 + CD28 may yield a more ployclonal cellular product 
as research has shown the preferential retention of a CD28 positive T-cell 
population (Kim, Brutkiewicz, and Broxmeyer 2002).  
 From this data, it appears that during the manufacturing with heterologous 
human PBMCs, there is a quick dramatic change in gene expression patterns 
which is maintained as the manufacturing continues. Additionally, there 
appears to exist multiple states of T cells, with both populations that 
maintained in a state of proliferation and those in a state of apoptosis and 
contraction. As the expansion continues, there is an evident loss of 
proliferative ability, likely due to the decrease in actively dividing T cells 







































Figure 30: The changes occurring during T-cell manufacturing.  
Early on in manufacturing cells seem to exist in two generalized states of 
either being pro-apoptotic or anti-apoptotic, with these two states being 
maintained throughout the manufacturing. As cells are manufactured, they 
lose their ability to respond to growth cytokines, lose telomere length, 













In addition to the loss throughout T-cell expansion, the starting expression 
of CD28 was shown to predict multiple manufacturing metrics, such as fold 
expansion and the final CD8 percentage. These correlations support a model 
in which CD28 expression, in the context of CD3 + CD28 manufacturing, 
serves as a master regulator for the T-cell manufacturing. I propose that this 
expression, or lack thereof, acts as an ex vivo bottleneck where the cells with 
CD28 expression will outperform the cells not expressing CD28. Given that 
minimum cell numbers must be reached for a therapeutic dosage, cell 
expansions are often elongated and, in this model, only a small percentage of 
the cells are actively expanding to reach this final dosage in older donors. This 
is a troubling scenario as the limited number of expanding cells endure shorter 
telomere lengths, increased differentiation, and loss of cytokine sensitivity as 
they carry the brunt of the expansion load.   
 To test this model out fully, I performed single molecule DNA sequencing 
to track T-cell clones throughout the expansion. There was a strong 
correlation between the number of T-cell clones that either expanded or 
contracted and the starting percentage of CD28 expression. In low CD28 
expressing starting populations, there is clear early cell death, evident by the 
negative population expansion and negative clonal divisions by day 4 in the 
expansion process (figure 24). This behavior was also evident when tracking 
the percentages of clones which expanded or contracted early on, with a small 
~1% of T-cell clones showing early expansion in the low CD28 population 
(figure 26). This cell death then potentially creates a homeostatic niche by 
which low frequency clones can begin dividing with less competition as 
suggested by the higher frequency of differentially abundant clones in lower 




bimodal distribution pattern in clonal divisions in low CD28 PBMC cultures 
(figure 25 and 26). Finally, the decline in unique T-cell clones in donors with 
lower CD28 expression firmly supports an ‘extinction’ bottleneck event by 
which clones which cannot survive the manufacturing are removed from the 
sampling pool (figure 25). It is intriguing to speculate that this loss of clonal 
diversity may impact the ability of T cell products to persist in vivo as weak 
non-cognate TCR:HLA interactions have been shown provide a growth signal 
stimulatory effect (Ernst et al. 1999). This event is analogous to a specific T-
cell ‘families’ being removed from the entire population of T cells. This model 
agrees with a recent discovery that CD28 induced 3BP2 drives late stage TCR 
independent activation and leads to prolonged T-cell proliferation ex vivo 
(Dimitriou et al. 2018). In a clinical setting, in which manufacturing is often 
ceased when cell number thresholds are met, this model would predict that 
lower CD28 starting cell populations will achieve an average of two times the 
number of cell divisions to achieve the same number of final cells (figure 26). 
With this data, I propose a model by which the starting percentage of CD28 
within a PBMC sample can model the behavior of the T-cell culture and the 
final product characteristics and that the CD28+ T-cells eventually become 














Figure 31: Bottleneck model of T-cell expansion with CD3 + CD28.  
Heterologous human PBMC T-cells (left panel circles) can be classified based 
on whether they express CD28 or not. Those that do express CD28 undergo a 
more rapid division (smiles) early on and during the expansion process, 
increasing in frequency during the expansion. As the expansion continues, 
these cells eventually become exhausted (frowns) and enter a T-cell 
senescence stage. As the T-cells move into this senescence stage, specific T-












 If we accept that this CD28 dependent bottleneck exists, a reasonable 
assumption is that heterogeneous patient populations will vary in their T cells 
“fitness” for CD3 + CD28 based T-cell expansion protocols. From a total of 4 
clinical CD19 trials, each patient’s clinical response was codified and then the 
patients were divided based on age.  Patients older than 45 performed 
approximately two times better in terms of objective response rates (partial 
response + complete response) when their cells were manufactured with CD3 
stimulation without the costimulation of CD28. An inverse relationship was 
seen when patients were younger than 45, in this case, patients performed 
nearly one and half times better when their cells were manufactured with CD3 
+ CD28 stimulation expansion protocols. Perhaps the CD28 stimulation in 
older patients creates a competitive expansion environment in which older 
patient highly differentiated T cells cannot survive, this would be a biological 
explanation and is supported by observations of T-cell trans interactions 
taking placing during expansion protocols (Klebanoff et al. 2016) and the 
higher susceptibility of differentiated T cells to survive reactive oxygen rich 
environments. It is an objective of my post-doctoral work to investigate the 
exact mechanism behind this age bias in T-cell manufacturing as it appears 
that the T-cell manufacturing process can be enhanced by personalization to 









The specific aims of this dissertation and the relevant conclusions are shown 
below: 
1) AIM: Develop an in vitro assay aimed at predicting long-term tumor control 
rather than short-term effector function  
Conclusion: The cytokine sensitivity assay (CSA) was developed to 
measure the proliferative potential of T cells post T-cell expansion protocols 
2) AIM: Compare the effect of in-vitro expansion durations on the quality of 
gene therapy transfer T-cells using the newly-developed assay and perform 
mechanism of action (MOA) studies 
Conclusion: Using the CSA, I tested the effects of elongated expansion 
protocols and was able to show that elongated expansions correlated with 
signs of functional senescence in CSA.  
Conclusion: MOA studies were performed, and it is my leading hypothesis 
that ex vivo bottlenecks exist in T-cell expansion protocols and these 
bottlenecks differentially effect manufacturing outcome based on the 
expression of CD28 in the presence of CD3 + CD28 manufacturing. Future 
work is needed to investigate whether similar bottlenecks exist in other 
manufacturing protocols.  
3) Determine the clinical relevance of the MOA studies using correlative 
studies aimed at testing the pre-clinical determined mechanism 
Conclusion: While I was not able to test the model using actual clinical 
manufactured T-cells, I was able to apply the bottleneck model to guide a 
clinical trial meta-analysis to show that patient age was a criterion for which 




needed to elucidate the complete clinical meaning of this model and how it 
can be used to tailor manufacturing for certain patient populations.  
Future Directions 
 With respect to nature of current clinical cellular therapy manufacturing, it 
is evident that there is a strong depersonalization of the personalized drug 
product. While there is great deal of patient immune-heterogeneity and thus a 
wide variability in the starting material used in manufacturing, the field is 
confined to a ‘one-size-fits-all’ manufacturing mentality. This dogmatic 
principle confines the flexibility in manufacturing and the ability to customize to 
the patient’s unique cellular phenotype. For example, from the clinical meta-
analysis, we see that there is an indication that the more elderly may benefit 
from a manufacturing in which CD3 is the sole source of T-cell stimulation.  
From my perspective, the restrictive nature of cellular manufacturing is 
impacted largely by the nature of Federal Drug Administration (FDA) 
regulation of cellular therapies in the same manner as drug compounds. While 
rigid processes, strict manufacturing lengths, and tight lot-to-lot variability may 
work in the manufacturing of an inert drug product, the nature of personalized 
cellular therapy likely entails the necessity for a more flexible manufacturing 
specification.  
 Moving forward, it is reasonable to imagine that a patient is first phenotype 
upon entering clinic and a customized manufacturing is tailor made to their 
unique specifications. For example, if you have a more exhausted cellular 
phenotype, perhaps a 4-1BBL stimulation is considered as there is evidence 
that it may restore a more naive CD28+ phenotype (Habib-Agahi, Jaberipour, 
and Searle 2009). Within the same thinking, sub-compartment isolation may 




Furthermore, the data from the CSA assay (figure 5) suggests that each 
patient may respond to certain cytokines better than others and thus an 
optimized cytokine cocktail may be in order. 
If we are to go to such a flexible modular manufacturing, then there will 
undoubtably be an increased pressure on the manufacturer to demonstrate 
the feasibility and logic behind their decisions. With such restrictions, it is likely 
that an increased effort will be required in the pre-clinical stages of 
development as a more complex process development will be required. It will 
require a strong academic-industry-regulatory alliance if we are to shoulder 
the increased demands in pursuit of truly personalized cellular therapies.  
 There is a selective pressure perspective that takes place during T-cell 
culturing and the pressures must be understood. The work presented here 
aims to be a small piece in a launching-off pad for personalized cellular 
medicine. Its aim is to highlight our diverse heterogeneity and questions the 
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